REG - AstraZeneca PLC - Filing of Form 20-F with SEC

AstraZenecaAnnouncement

04/03/2020 07:00

RNS Number : 9133E
  
AstraZeneca PLC
  
04 March 2020
  
 

4 March 2020 07:00 GMT
 
Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission
 
AstraZeneca PLC (the Company) announced today that, on 3 March 2020, it filed its 2019 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at www.sec.gov and also on the Company's website at www.astrazeneca.com. The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.




Media Relations


 


 




Gonzalo Viña 


 


+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharmaceuticals


+44 203 749 5906




Angela Fiorin


BioPharmaceuticals


+44 1223 344 690




Jennifer Hursit


Other 


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677




Investor Relations


 


 




Thomas Kudsk Larsen


 


+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharmaceuticals 
(Cardiovascular, Metabolism)


+44 203 749 5711




Nick Stone


BioPharmaceuticals (Renal) Environmental, Social and Governance


+44 203 749 5716




Josie Afolabi


BioPharmaceuticals (Respiratory)
 


+44 203 749 5631




Tom Waldron


Other medicines


+44 7385 033 717




Craig Marks


Finance
Fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access
Retail investors


+44 203 749 5824




US toll-free


 


+1 866 381 72 77






Adrian Kemp

Company Secretary

AstraZeneca PLC
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCSSUFADESSESD